| Press Release
By Tessera Therapeutics
| Press Release
By Tessera Therapeutics
| News
What Makes a Company a Great Place to Work? Moderna and Tessera Share Their Insights
From BioSpace
| Company Statement
Tessera Therapeutics Awarded the Prix Galien USA 2023 for Best Startup
By Tessera Therapeutics
| Press Release
By Tessera Therapeutics
| Press Release
By Tessera Therapeutics
| Press Release
Tessera Therapeutics Names Cynthia M. Patton as General Counsel and Secretary
By Tessera Therapeutics
| News
From Fierce Biotech
| Press Release
By Tessera Therapeutics
| News
Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases
From Genetic Engineering & Biotechnology News
| News
Can “Gene Writing” Deliver What Gene Editing Can’t?
From The Scientist
| News
From Boston Globe
| News
BRIEF—bluebird bio exec flies nest to join Tessera Therapeutics
From The Pharma Letter
| News
Bluebird exec spreads wings, heads over to Tessera for 'irresistible opportunity'
From Fierce Biotech
| News
From Endpoints News
| News
Bluebird's Eggimann joins Tessera team
From BioCentury
| News
Tessera Therapeutics Expands Leadership and Board
From Business Wire
| News
Biomanufacturing Parallels the Semiconductor Chip Revolution
From Genetic Engineering & Biotechnology News
| News
Non-CRISPR Gene Editing Platforms Make the Cut … or Avoid Making It
From Genetic Engineering & Biotechnology News
| News
Michael Severino trades in AbbVie perch for CEO role at Flagship’s gene medicines biotech Tessera
From Endpoints News
| News
From Fierce Biotech
| News
Former AbbVie executive Severino joins Flagship-backed startup as CEO
From BioPharma Dive
| News
From Business Wire
| News
Tessera snags $300M+ for gene writing tech
From PitchBook
| News
Flagship-backed 'gene-writing' startup Tessera raises $300M
From Boston Business Journal
| News
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
From Business Wire